BURLINGTON, Mass.--(BUSINESS WIRE)--Terason, the market leading producer of high performance Laptop Ultrasound™ imaging systems today announced that it has reached an agreement with SenoRx, Inc. (NASDAQ: SENO) to provide its Terason t3000 ultrasound for the launch of an additional model of the SenoSonix™ System. Like the original SenoSonix, the new model is an integration of SenoRx’s EnCor® breast biopsy system with ultrasound imaging. This new version of the device incorporates a microminiaturization ultrasound technology that combines personal computing power and flexibility designed, developed and marketed by Terason. This versatile ultrasound technology coupled with SenoRx’s proprietary EnCor vacuum-assisted biopsy technology results in an attractive alternative model of the SenoSonix System for customers. The modular design and sophisticated imaging architecture are now available in a reduced footprint with increased portability. The original SenoSonix System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October 2007 and CE Mark approval in April 2008.
